Novo Nordisk meets upgraded guidance, sets new revenue record
The Danish drugmaker’s top and bottom lines have increased considerably.
by christian bundgaard, translated by daniel pedersen
Pharmaceutical firm Novo Nordisk comes out strong from fiscal 2022, which was marked by financial uncertainty and supply issues specifically for the firm’s heralded new obesity drug, Wegovy.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk doubles obesity sales in 2022
For subscribers
Novo Nordisk predicts wide range for 2023 sales growth
For subscribers
Bank expects strong 2022 conclusion from Novo Nordisk
For subscribers
.jpg&w=384&q=75)
